Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
WEB3 days ago · The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. ... the news and media division of Thomson Reuters, is ...
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
WEB2 days ago · The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. Sofinnova Venture Partners currently has a 7.3% ...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEB3 days ago · September 18, 2024 at 4:53 PM EDT. Save. BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 ...
Obesity drug developer BioAge sets IPO terms (Pending:BIOA)
WEB2 days ago · Obesity drug developer BioAge Labs has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the ...
Obesity drugmaker BioAge targets $158 million in IPO
WEB3 days ago · Obesity drugmaker BioAge targets $158 million in IPO BY David Morris and Bloomberg The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday.
BioAge Labs Files For $100M IPO, Becomes The New Entrant In …
WEBSep 4, 2024 · BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
WEBBioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement. The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday with the US Securities and Exchange Commission.
Eli Lilly partner BioAge files for US IPO | Reuters
WEBSept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), filed for an initial public offering in the United States on Tuesday as it...
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
WEBSep 3, 2024 · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering.
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
WEBSep 4, 2024 · BioAge will use the IPO funds to start a proof-of-concept study of azelaprag in insulin sensitivity, with an eye toward expanding its indication. A chunk of the IPO raise will also go toward developing its NLRP3 blocker for neuroinflammation.
- Some results have been removed